

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Shanghai Bio-heart Biological Technology Co., Ltd.

上海百心安生物技術股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2185)

POLL RESULTS OF THE 2022 FIRST EXTRAORDINARY GENERAL MEETING HELD ON NOVEMBER 10, 2022; CHANGE OF DIRECTOR; CHANGE OF COMPOSITION OF REMUNERATION COMMITTEE AND CHANGE OF SUPERVISOR

The Board is pleased to announce that all the resolutions set out in the Notice of EGM were duly passed by the Shareholders by way of poll at the EGM.

The 2022 first extraordinary general meeting (the “**EGM**”) of Shanghai Bio-heart Biological Technology Co., Ltd. (the “**Company**”) was convened at 2:00 p.m. on Thursday, November 10, 2022 at Fourth Floor, Building 7, 59 Kaiqing Road, East Zhangjiang Hi-Tech Park, Pudong New Area, Shanghai, PRC. References are made to the notice (the “**Notice of the EGM**”) and the circular (the “**Circular**”) of the Company both dated October 25, 2022. Unless the context requires otherwise, capitalized terms used herein shall have the same meanings as those defined in the Circular.

The EGM was convened by the Board in accordance with the Company Law of the PRC and the Articles of Association, and chaired by Mr. Philip Li Wang, the Chairman of the Board and an executive Director of the Company.

ATTENDANCE AT THE EGM

As at the date of the EGM, the total number of issued ordinary Shares was 243,937,000 Shares, comprising 61,606,116 H Shares, 100,107,425 Domestic Shares and 82,223,459 Unlisted Foreign Shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against or abstain from voting on the proposed resolutions at the EGM.

Shareholders (including proxies) representing 147,294,864 Shares (including 24,556,292 H Shares, 69,379,310 Domestic Shares and 53,359,262 Unlisted Foreign Shares) or approximately 60.38% of the total issued Shares of the Company attended the EGM.

To the best knowledge, information and belief of the Company: (1) there were no Shares entitling the holder to attend and abstain from voting in favor of the resolutions proposed at the EGM as set out in Rule 13.40 of the Hong Kong Listing Rules; (2) no Shareholder was required under the Hong Kong Listing Rules to abstain from voting on the resolutions proposed at the EGM; and (3) no party has stated any intention in the Circular to vote against or to abstain from voting on any of the resolutions proposed at the EGM.

Apart from Ms. Li Cai, all Directors, namely Mr. Philip Li Wang, Mr. Yunqing Wang, Mr. Quan Zhou, Mr. Ji Chen, Mr. Charles Sheung Wai Chan, Mr. Xubo Lu and Mr. George Chien Cheng Lin, attended the EGM either in person or by electronic means.

POLL RESULTS OF THE EGM

The poll results of the resolutions proposed at the EGM are as follows:

Ordinary Resolutions		Number of votes (%)		
		For	Against	Abstain
1.	To consider and approve the proposal for the appointment of Ms. Peili Wang (王佩麗) as an executive Director.	147,294,864 (100.00%)	0 (0.00%)	0 (0.00%)
2.	To consider and approve the proposal for the appointment of Mr. Lei Zhu (朱磊) as a Supervisor.	147,294,864 (100.00%)	0 (0.00%)	0 (0.00%)

Note: All percentages are rounded to two decimal places.

As more than half of the votes were cast in favour of Ordinary Resolutions No. 1 to No. 2, all resolutions proposed at the EGM were duly passed by way of poll by the Shareholders. The Company's H share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the EGM for the purpose of vote-taking.

CHANGE OF DIRECTOR

Upon the approval by the Shareholders at the EGM, Ms. Peili Wang (王佩麗) (“**Ms. Wang**”) was appointed as an executive Director with effect from November 10, 2022. She will hold office until the end of the current session of the Board. The biographical details of Ms. Wang were set out in the Circular. As at the date of this announcement, there was no change in such information.

Upon the appointment of Ms. Wang, Ms. Li Cai (蔡俐) (“**Ms. Cai**”) would resign from her position as a non-executive Director and a member of the Remuneration Committee of the Company. Ms. Cai has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the Shareholders or the Stock Exchange.

CHANGE OF COMPOSITION OF REMUNERATION COMMITTEE

Following the appointment of Ms. Wang, Mr. George Chien Cheng Lin (林潔誠), an independent non-executive Director, was appointed as a member of the Remuneration Committee, with effect from November 10, 2022.

CHANGE OF SUPERVISOR

Upon the approval by the Shareholders at the EGM, Mr. Lei Zhu (朱磊) (“**Mr. Zhu**”) was appointed as a Supervisor with effect from November 10, 2022. He will hold office until the end of the current session of the Board of Supervisors. The biographical details of Mr. Zhu were set out in the Circular. As at the date of this announcement, there was no change in such information.

Upon the appointment of Mr. Zhu, Ms. Wang would resign from her position as a Supervisor. Ms. Wang has confirmed that she has no disagreement with the Board of Supervisors and there is no matter relating to her resignation that needs to be brought to the attention of the Shareholders or the Stock Exchange.

By order of the Board
Shanghai Bio-heart Biological Technology Co., Ltd.
Philip Li WANG
Chairman and executive Director

Shanghai, the People’s Republic of China, November 10, 2022

As at the date of this announcement, the Board of the Company comprises Mr. Philip Li WANG as Chairman and executive Director, Mr. Yunqing WANG and Ms. Peili WANG as executive Directors, Mr. Quan ZHOU and Mr. Ji CHEN as non-executive Directors, and Mr. Charles Sheung Wai CHAN, Mr. Xubo LU and Mr. George Chien Cheng LIN as independent non-executive Directors.